PMID- 21885500
OWN - NLM
STAT- MEDLINE
DCOM- 20120420
LR  - 20151119
IS  - 1499-2752 (Electronic)
IS  - 0315-162X (Linking)
VI  - 38
IP  - 11
DP  - 2011 Nov
TI  - Levels of serum matrix metalloproteinase-3 correlate with disease activity in the 
      enthesitis-related arthritis category of juvenile idiopathic arthritis.
PG  - 2482-7
LID - 10.3899/jrheum.110352 [doi]
AB  - OBJECTIVE: Serum matrix metalloproteinase-3 (MMP-3) has been shown to reflect 
      disease activity in ankylosing spondylitis (AS) and rheumatoid arthritis. 
      Elevated levels have been found in juvenile idiopathic arthritis (JIA). In the 
      enthesitis-related arthritis category of JIA (JIA-ERA), we studied whether serum 
      MMP-3 levels and ratios of MMP-3/tissue inhibitor of metalloproteinase (TIMP-1) 
      are correlated with disease activity and whether they are sensitive to change in 
      disease activity. METHODS: A total of 54 patients with JIA-ERA (International 
      League of Associations for Rheumatology criteria) were enrolled for study. 
      Baseline disease activity measures included tender and swollen joint counts, 
      Maastricht AS Enthesitis Score, Bath AS Disease Activity Index (BASDAI), Bath AS 
      Functional Index (BASFI), patient assessment of pain and global disease activity, 
      physician assessment of global disease activity, and erythrocyte sedimentation 
      rate (ESR). Serum MMP-3 and TIMP-1 levels were measured using ELISA. A group of 
      24 patients were followed up for longitudinal study. RESULTS: The mean age of 54 
      patients (48 males) at disease onset was 11.8 +/- 4.19 years and duration of 
      disease was 5.2 +/- 4.3 years. Median ESR was 65 mm/h (range 46.5-97) and median 
      BASDAI was 3.4 (range 2.5-4.7). Median MMP-3, TIMP-1, and MMP-3/TIMP-1 ratio were 
      50.4 ng/ml (IQR 13.0-193.8), 228.9 ng/ml (IQR 108.2-290.4), and 0.3 (IQR 
      0.07-1.13), respectively. At inclusion MMP-3 levels correlated directly with 
      various disease activity measures: tender joint count (TJC; r = 0.60), swollen 
      joint count (SJC; r = 0.45), BASFI (r = 0.29), BASDAI (r = 0.32), ESR (r = 0.49), 
      physician global assessment (r = 0.40), patient visual analog scale for pain (r = 
      0.28), and patient global assessment (r = 0.38; all p < 0.05). MMP-3/TIMP-1 ratio 
      correlated only with TJC (r = 0.51), SJC (r = 0.39), and ESR (r = 0.34; p < 
      0.05). At followup, change in MMP-3 correlated with changes in TJC (r = 0.42) and 
      SJC (r = 0.44; p < 0.05), while change in ESR did not correlate with change in 
      any disease activity measure. CONCLUSION: MMP-3 levels are a good marker for 
      disease activity in JIA-ERA.
FAU - Viswanath, Vishad
AU  - Viswanath V
AD  - Department of Clinical Immunology, Sanjay Gandhi Postgraduate Institute of 
      Medical Sciences, Lucknow, India. amita@sgpgi.ac.in
FAU - Myles, Arpita
AU  - Myles A
FAU - Dayal, Rajeshwar
AU  - Dayal R
FAU - Aggarwal, Amita
AU  - Aggarwal A
LA  - eng
PT  - Journal Article
DEP - 20110901
PL  - Canada
TA  - J Rheumatol
JT  - The Journal of rheumatology
JID - 7501984
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Biomarkers)
RN  - 0 (Tissue Inhibitor of Metalloproteinase-1)
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
SB  - IM
MH  - Adolescent
MH  - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
MH  - Antirheumatic Agents/therapeutic use
MH  - Arthritis, Juvenile/*blood/*diagnosis/drug therapy
MH  - Biomarkers/blood
MH  - Blood Sedimentation
MH  - Child
MH  - Child, Preschool
MH  - *Disease Progression
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Longitudinal Studies
MH  - Male
MH  - Matrix Metalloproteinase 3/*blood
MH  - Pain Measurement
MH  - *Severity of Illness Index
MH  - Tissue Inhibitor of Metalloproteinase-1/blood
MH  - Young Adult
EDAT- 2011/09/03 06:00
MHDA- 2012/04/21 06:00
CRDT- 2011/09/03 06:00
PHST- 2011/09/03 06:00 [entrez]
PHST- 2011/09/03 06:00 [pubmed]
PHST- 2012/04/21 06:00 [medline]
AID - jrheum.110352 [pii]
AID - 10.3899/jrheum.110352 [doi]
PST - ppublish
SO  - J Rheumatol. 2011 Nov;38(11):2482-7. doi: 10.3899/jrheum.110352. Epub 2011 Sep 1.